Evaluating muscle loss in liver cancer patients using blood tests and imaging
Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma
NA · CHU de Reims · NCT06475118
This study is testing if blood tests and imaging can help doctors better understand muscle loss in patients with liver cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 139 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims (other) |
| Locations | 1 site (Reims) |
| Trial ID | NCT06475118 on ClinicalTrials.gov |
What this trial studies
This study aims to assess sarcopenia, or muscle loss, in patients diagnosed with hepatocellular carcinoma (HCC) by comparing serum levels of myokines and imaging methods. Myokines are substances in the blood that can influence muscle mass, and their levels may provide insights into the severity of sarcopenia. The study will utilize dynamometry measurements and calculate the Skeletal Muscle Index (SMI) from CT scans to evaluate muscle mass. By improving the assessment of sarcopenia, the study seeks to enhance patient management and outcomes in those with HCC.
Who should consider this trial
Good fit: Ideal candidates for this study are patients newly diagnosed with hepatocellular carcinoma, regardless of the degree of liver fibrosis.
Not a fit: Patients with active cancers other than hepatocellular carcinoma or uncontrolled HIV infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better assessment and management of sarcopenia in liver cancer patients, potentially improving their treatment outcomes and quality of life.
How similar studies have performed: While the approach of using myokines for assessing sarcopenia is promising, it is relatively novel and has not been extensively tested in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * New diagnosis of HCC made by radiology and/or histopathology according to EASL criteria, regardless of the degree of hepatic fibrosis (METAVIR F0-F4) * Availability of a pre-therapeutic three-phase contrast-enhanced abdominal-pelvic CT scan. Non-inclusion criteria: * Presence of an active cancer other than HCC * Uncontrolled HIV infection.
Where this trial is running
Reims
- Damien JOLLY — Reims, France (RECRUITING)
Study contacts
- Study coordinator: Elia GIGANTE
- Email: egigante@chu-reims.fr
- Phone: 03 26 78 33 43
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sarcopenia, Hepatocellular Carcinoma, myokines